✦ LIBER ✦

Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A

✍ Scribed by M. MATYSIAK; H. BOBROWSKA; W. BALWIERZ; A. CHYBICKA; J. R. KOWALCZYK; R. SHAIKH-ZAIDI; K. GILLANDERS; C. H. DASH

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of Optivate®, a high-pu

✍ A. DMOSZYNSKA; A. HELLMANN; T. BAGLIN; D. O’SHAUGNESSY; J. TRELINSKI; K. KULICZK 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB

Experience with Optivate®, a new high pu

✍ C. R. M. HAY; A. HELLMANN; A. DMOSZYNSKA; T. BAGLIN; D. O’SHAUNESSEY; M. MAKRIS; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

Clinical assessment of Optivate®, a high

✍ A. DMOSZYNSKA; K. KULICZKOWSKI; A. HELLMANN; J. TRELINSKI; J. KLOCZKO; T. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

Higher recovery of factor VIII (FVIII) w

✍ T. INOUE; M. SHIMA; M. TAKEYAMA; T. MATSUMOTO; K. NISHIYA; I. TANAKA; Y. SAKURAI 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

Immune tolerance induction with high von

✍ H. PLATOKOUKI; H. PERGANTOU; P. XAFAKI; A. KOMITOPOULOU; S. ARONIS 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 33 KB

Immune tolerance therapy utilizing facto

✍ M. A. H. KURTH; D. DIMICHELE; C. SEXAUER; J. M. SANDERS; M. TORRES; S. C. ZAPPA; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB